{"database": "lobbying", "table": "lobbying_activities", "rows": [[1162562, "3890b669-0f7c-4af0-aeb2-2d65bbd7cba3", "Q3", "SHIRE PHARMACEUTICALS LLC", 323477, "SHIRE PHARMACEUTICALS LLC", 2011, "third_quarter", "PHA", "Life Sciences Investment Act; orphan drugs; end stage renal disease (ESRD) bundling of non-injectable oral equivalents; ESRD Quality Incentive program; Prescription Drug User Fee program; reimbursements; drug shortages; DEA quotas", "SENATE", null, 80000, 0, 0, "2011-10-19T20:14:18.343000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1162562"], "units": {}, "query_ms": 52.22550604958087, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}